Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Loss of MAGEL2 in Prader-Willi syndrome leads to decreased secretory granule and neuropeptide production
Helen Chen, A. Kaitlyn Victor, Jonathon Klein, Klementina Fon Tacer, Derek J.C. Tai, Celine de Esch, Alexander Nuttle, Jamshid Temirov, Lisa C. Burnett, Michael Rosenbaum, Yiying Zhang, Li Ding, James J. Moresco, Jolene K. Diedrich, John R. Yates III, Heather S. Tillman, Rudolph L. Leibel, Michael E. Talkowski, Daniel D. Billadeau, Lawrence T. Reiter, Patrick Ryan Potts
Helen Chen, A. Kaitlyn Victor, Jonathon Klein, Klementina Fon Tacer, Derek J.C. Tai, Celine de Esch, Alexander Nuttle, Jamshid Temirov, Lisa C. Burnett, Michael Rosenbaum, Yiying Zhang, Li Ding, James J. Moresco, Jolene K. Diedrich, John R. Yates III, Heather S. Tillman, Rudolph L. Leibel, Michael E. Talkowski, Daniel D. Billadeau, Lawrence T. Reiter, Patrick Ryan Potts
View: Text | PDF
Research Article Cell biology Neuroscience

Loss of MAGEL2 in Prader-Willi syndrome leads to decreased secretory granule and neuropeptide production

  • Text
  • PDF
Abstract

Prader-Willi syndrome (PWS) is a developmental disorder caused by loss of maternally imprinted genes on 15q11-q13, including melanoma antigen gene family member L2 (MAGEL2). The clinical phenotypes of PWS suggest impaired hypothalamic neuroendocrine function; however, the exact cellular defects are unknown. Here, we report deficits in secretory granule (SG) abundance and bioactive neuropeptide production upon loss of MAGEL2 in humans and mice. Unbiased proteomic analysis of Magel2pΔ/m+ mice revealed a reduction in components of SG in the hypothalamus that was confirmed in 2 PWS patient–derived neuronal cell models. Mechanistically, we show that proper endosomal trafficking by the MAGEL2-regulated WASH complex is required to prevent aberrant lysosomal degradation of SG proteins and reduction of mature SG abundance. Importantly, loss of MAGEL2 in mice, NGN2-induced neurons, and human patients led to reduced neuropeptide production. Thus, MAGEL2 plays an important role in hypothalamic neuroendocrine function, and cellular defects in this pathway may contribute to PWS disease etiology. Moreover, these findings suggest unanticipated approaches for therapeutic intervention.

Authors

Helen Chen, A. Kaitlyn Victor, Jonathon Klein, Klementina Fon Tacer, Derek J.C. Tai, Celine de Esch, Alexander Nuttle, Jamshid Temirov, Lisa C. Burnett, Michael Rosenbaum, Yiying Zhang, Li Ding, James J. Moresco, Jolene K. Diedrich, John R. Yates III, Heather S. Tillman, Rudolph L. Leibel, Michael E. Talkowski, Daniel D. Billadeau, Lawrence T. Reiter, Patrick Ryan Potts

×

Figure 3

SG proteins are reduced in human iN with PWS deletion.

Options: View larger image (or click on image) Download as PowerPoint
SG proteins are reduced in human iN with PWS deletion.
(A) Transcript le...
(A) Transcript levels of MAP2 and DCX are significantly increased in control and PWS iN at 14 days postinduction. PWS iN are normalized to averaged control iN. Each data point represents 1 induction experiment (n = 3), plotted with mean ± SD and analyzed by 1-way ANOVA. (B) Transcript levels of MAGEL2 are significantly increased in control iN at 14 days postinduction. Each data point represents 1 induction experiment (n = 3), plotted as mean ± SD and analyzed by 1-way ANOVA. (C) Western blot analysis confirms reduced expression of PCSK1, PCSK2, CHGB, and CPE in PWS iN at 14 days postinduction. GAPDH served as loading control. (D) Quantification of Western blot analysis showed reduced expression of PCSK1, PCSK2, CHGB, and CPE in PWS iN. Each target protein is first normalized to GAPDH, and then PWS iN is normalized to averaged control iN. Each data point represents 1 induction experiment (n = 4), plotted as mean ± SD and analyzed by 1-way ANOVA; *P < 0.05. (E) Western blot analysis confirms reduced expression of PCSK1, PCSK2, CHGB, and CPE in PWS iN compared with control iN at 3, 7, 10, and 14 days postinduction. GAPDH served as loading control.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts